AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing

AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai Press Release – 21 March 2025 – AstraZeneca today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance … Continue reading AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing

Impact Newswire28/03/202528/03/2025

United States

Crown Bioscience Appoints John Gu as Chief Executive Officer

News – San Diego, USA—March 13, 2025 — Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, has appointed John Gu as its new Chief Executive Officer (CEO). Following his tenure as interim CEO and his role as Chief Operating Officer (COO), John Gu is recognized as an esteemed leader with … Continue reading Crown Bioscience Appoints John Gu as Chief Executive Officer

Impact Newswire20/03/202520/03/2025

Global

Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery

New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies Press Release – February 20, 2025 – VANCOUVER, British Columbia – Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today announced the completion of its oversubscribed $US5.5 million Seed extension round. Enki™ empowers biopharmaceutical chemistry teams to efficiently discover and optimize novel hits and … Continue reading Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery

Impact Newswire25/02/202525/02/2025

United States

Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer

Proven Pharmaceutical Executive Brings Over 30 Years of R&D Experience to Supercharge the Company’s Next Phase of Growth Seasoned Biotechnology Leader Mike Varney, Ph. D., Appointed as Lead Independent Director of the Board Press Release – SAN FRANCISCO, CALIFORNIA, FEBRUARY 18, 2025 – Atomwise, a leader in leveraging machine learning and artificial intelligence (ML/AI) to advance small molecule drug discovery, today announced the appointment of Steve … Continue reading Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer

Impact Newswire24/02/202524/02/2025

Europe

Artificial intelligence is speeding up the development of the next generation of biostimulants

Syngenta Crop Protection and TraitSeq announce a pioneering collaboration which could help farmers transition to more sustainable practices. Press Release – January 09, 2025 – BASEL, Switzerland & NORWICH, England – Syngenta and the pioneering artificial intelligence (AI) company TraitSeq are combining forces to use the full power of AI for the development of innovative, high-performance biostimulants. Syngenta, a world leader in developing the next … Continue reading Artificial intelligence is speeding up the development of the next generation of biostimulants

Impact Newswire16/01/202516/01/2025